Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
- Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation
- Dr. Lara Campana to present preclinical data on intravenous Regenerative Macrophage Therapy for decompensated cirrhosis
Edinburgh and London, UK, 6 October 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announces that interim data from its Phase I/II EMERALD trial for RTX001 has been accepted as a late-breaking presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, being held in Denver, Colorado from 5–9 November 2026.
